Search Results

PharmAbcine (KRX: 208340ks), a biotech company focusing on the development of antibody therapeutics, announced on August 31 that it had signed a contract manufacturing organization(CMO) agreement with Binex, a leading biologics CDMO(Contract Development and Manufacturing Organization) company in Korea.

PharmAbcine (KRX: 208340) (GM: Jin-san Yoo), biotech company focusing on the development of antibody therapeutics, announced on 18th that it had signed a contract manufacturing organization(CMO) agreement with biologics contract development and manufacturing organization (CDMO) Binex for additional production of investigationa

According to the latest research by nova one advisor, the global biopharmaceuticals contract manufacturing market size was exhibited at USD 19.89 billion in 2023 and is projected to hit around USD 31.92 billion by 2032, growing at a CAGR of 5.4% during the forecast period 2023 to 2032.

SK bioscience announced that Richard Kensinger, PhD, former Director and Head of Drug Substance Process Development in Sanofi Pasteur and former Executive Director of Process Development and Protein Sciences at Affinivax Inc. has joined in ‘SK bioscience USA Inc.’ as Vice President of R&D Project Management.

According to Latest Study, the global biopharmaceuticals contract manufacturing market was surpassed at USD 17.1 billion in 2021 and is expected to hit around USD 27.5 billion by 2030, growing at a CAGR of 5.42% from 2022 to 2030.

Latest Study on “Biopharmaceutical CMO And CRO Market Size, Share, Trends, Growth, Production, Consumption, Revenue, Company Analysis and Forecast 2022-2030”.

A recent research report points to the CDMO market heating up. P&S projected the global biologics CDMO market would hit $31.839 million by 2030.